BVI’s Trifocal IOL Gains FDA Approval for U.S. Market

WALTHAM, Mass.—BVI, a global ophthalmic device company, announced that the Food and Drug Administration (FDA) has approved its FineVision HP trifocal intraocular lens (IOL) for the U.S. market. The company stated that FineVision HP is the world's first trifocal IOL, with over 15 years of clinical success and millions of implantations globally. This approval of the third-generation trifocal IOL is expected to expand advanced lens options available to patients in the U.S, the announcement noted.